Biotechnology

Filter

Current filters:

None

Popular Filters

57 to 81 of 2523 results

Effective new cholesterol treatments will come at great cost to health care system, says CVS

Effective new cholesterol treatments will come at great cost to health care system, says CVS

18-02-2015

The new class of cholesterol drugs could provide successful treatment to millions of Americans, but the…

BiotechnologyCVS HealthGastro-intestinalsMarkets & MarketingPricingUSA

Positive Ph III results for Navidea’s Lymphoseek in head and neck cancer

17-02-2015

US biotech firm Navidea Biopharmaceuticals today announced positive peer-reviewed publication of results…

BiotechnologyLymphoseekNavidea BiopharmaceuticalsOncologyResearch

Australia to subsidize Genzyme’s Pompe disease drug Myozyme for young patients

Australia to subsidize Genzyme’s Pompe disease drug Myozyme for young patients

17-02-2015

Australia’s Minister for Health Sussan Ley said today that she has approved a life-saving drug that…

AustraliaBiotechnologyFinancialGenzymeHealthcareMyozymeRare diseasesSanofi

US Orphan Drug status for Bexion’s Saposin C for glioblastoma

US Orphan Drug status for Bexion’s Saposin C for glioblastoma

17-02-2015

Privately-held US biotech firm Bexion Pharmaceuticals has received Orphan Drug designation for the US…

Bexion PharmaceuticalsBiotechnologyBXQ-350OncologyRegulationSaposin CUSA

Biotie receives positive opinion on orphan drug status for BTT1023 from EMA

Biotie receives positive opinion on orphan drug status for BTT1023 from EMA

17-02-2015

Finnish biotech and pharma company Biotie has received a positive opinion from the European Medicines…

BiotechnologyBiotie TherapiesFinlandNephrology and HepatologyRegulation

Call for transitional arrangements for Australia’s R&D Tax incentive cap

Call for transitional arrangements for Australia’s R&D Tax incentive cap

17-02-2015

The passage of unwelcome legislation last week to cap claims on the Australian Research and Development…

AustraliaBiotechnologyFinancialPoliticsResearch

Angle raises $11.2 million to aid development of Parsortix cancer cell filter

Angle raises $11.2 million to aid development of Parsortix cancer cell filter

16-02-2015

UK-based medtech company Angle has raised £7.3 million ($11.2 million) through issuing new shares. It…

AngleBiotechnologyErbituxFinancialOncologyResearch

Actelion posts strong 2014 earnings growth, but sales shy of expectations

Actelion posts strong 2014 earnings growth, but sales shy of expectations

16-02-2015

Switzerland-based Actelion this morning reported financial results for full-year 2014, showing that sales…

ActelionBiotechnologyFinancialRespiratory and Pulmonary

Ono signs deal with Dako for Opdivo companion diagnostic test

Ono signs deal with Dako for Opdivo companion diagnostic test

16-02-2015

Japanese pharma company Ono Pharmaceutical and Danish diagnostic provider Dako have signed a new partnership…

BiotechnologyDakoJapanLicensingOncologyOno PharmaceuticalOpdivo

Intrexon to acquire Belgium's ActoGeniX, bringing new generation of orally-delivered biotherapeutics

13-02-2015

US synthetic biology focussed US firm Intrexon has entered into a definitive agreement to acquire ActoGeniX,…

ActoGeniXBiotechnologyIntrexonMergers & Acquisitions

Tecfidera, first-line oral treatment for multiple sclerosis, approved in India

13-02-2015

US biotech major Biogen Idec’s Indian subsidiary has received approval of the first oral therapy for…

Biogen IdecBiotechnologyIndiaNeurologicalRegulationTecfidera

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

13-02-2015

French pharma major Sanofi subsidiary Genzyme has reported positive extension study data from its Phase…

BiotechnologyCerdelgaGenzymeRare diseasesResearchSanofi

NICE final draft guidance does not recommend pomalidomide for blood cancer

NICE final draft guidance does not recommend pomalidomide for blood cancer

13-02-2015

The England medical costs watchdog the National Institute for Health and Care excellence (NICE) has issued…

BiotechnologyCelgene CorpImnovidOncologypomalidomidePricingRegulationUK

Strong 2014 financials from Shire, bolstered by

Strong 2014 financials from Shire, bolstered by "break fee"

12-02-2015

Shares of Ireland-headquartered Shire gained 4.6% to £49.97, after the drugmaker reported pretax profit…

BiotechnologyFinancialRare diseasesShire

AusBiotech slams government moves on R&D Tax Incentive deals

12-02-2015

The Australian government’s shock deal with the Palmer United Party and Independent Senator Xenophon…

AustraliaBiotechnologyFinancialPoliticsResearch

Further approvals for ThromboGenics’ Jetrea

12-02-2015

Belgian biotech company ThromboGenics, which is focused on developing and commercializing innovative…

AlconArgentinaBiotechnologyIsraelJetreaNovartisOphthalmicsRegulationThromboGenics

TiGenix and Lonza sign agreement for the manufacture of Crohn’s disease treatment

TiGenix and Lonza sign agreement for the manufacture of Crohn’s disease treatment

12-02-2015

Swiss CMO Lonza and Belgian cell therapy firm TiGenix have agreed that Lonza will manufacture material…

BiotechnologyGastro-intestinalsLicensingLonzaTiGenixUSA

Voyager inks up to $845 million deal with Genzyme on novel CNS products

Voyager inks up to $845 million deal with Genzyme on novel CNS products

12-02-2015

US gene therapy start-up company Voyager Therapeutics has entered into a major strategic collaboration…

BiotechnologyGenzymeLicensingNeurologicalResearchSanofiUSAVoyager Therapeutics

CSL delivers solid first-half financials, but guidance disappoints

11-02-2015

Australian plasma fractionation specialist CSL Limited has today announced a net profit after tax (NPAT)…

BiotechnologyCSL LimitedFinancialHematologyVaccines

Anthera reports positive interim analysis of Phase III blisibimod trial

11-02-2015

US development stage biopharma company Anthera Pharmaceuticals saw its share rocket 25% on Wednesday…

Anthera PharmaceuticalsAnti-Arthritics/RheumaticsBiotechnologyblisibimodResearch

No new bidders emerge for Dendreon, so Valeant gets Provenge

No new bidders emerge for Dendreon, so Valeant gets Provenge

11-02-2015

US biotech firm Dendreon revealed yesterday that the bid deadline provided by the Court-approved bidding…

BiotechnologyDendreonMergers & AcquisitionsOncologyProvengeValeant Pharmaceuticals International

Seattle Genetics posts losses but beats analyst forecasts

Seattle Genetics posts losses but beats analyst forecasts

11-02-2015

Bothell, Washington, USA-headquartered oncology specialist Seattle Genetics managed to beat analyst estimates…

AdcetrisBiotechnologyFinancialOncologySeattle GeneticsUSA

Pfenex soars on Lucentis biosimilar deal with Hospira

Pfenex soars on Lucentis biosimilar deal with Hospira

10-02-2015

Shares of US clinical-stage biotech firm Pfenex leapt 28% to $8.85 in morning trading, after the company…

BiosimilarsBiotechnologyGenentechGlobalHospiraLicensingLucentisNovartisOphthalmicsPF582PfenexResearchRoche

Regeneron sees strong Eylea sales; financials beat expectations

Regeneron sees strong Eylea sales; financials beat expectations

10-02-2015

US biotech firm Regeneron Pharmaceuticals today announced financial results for the fourth quarter and…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneron PharmaceuticalsSanofi

57 to 81 of 2523 results

Back to top